Key facts
- It has raised $11.3M; the latest was Seed Round ($11.1M) in May 2024.
- Notable investors include Bpifrance, European Commission, Elaia Partners, Noshaq, France 2030 — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for HEPHAISTOS-Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for HEPHAISTOS-Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HEPHAISTOS-Pharma
Developer of an immunotherapy platform designed to produce the next generation of oncology treatments. The company's platform provides active and non-specific immuno-stimulants to potentiate commercialized antibodies, by turning cold tumors hot, but also very effective as single agents against cancers with unmet medical needs and boost the immune system, enabling the healthcare industry to treat incurable cancers efficiently by stimulating an immune response and turning hidden cold tumors into hot targets for the immune system.
- Sector
- Healthcare
- HQ
- Orsay, France
- Founded
- 2018
- Employees
- 9
- Website
- hephaistos-pharma.fr/
- Ownership
- Privately Held (backing)
HEPHAISTOS-Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HEPHAISTOS-Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HEPHAISTOS-Pharma in its N-PORT filings yet. We sweep new filings monthly.